Xencor reported $52.65M in Cash and Equivalent for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Alnylam Pharmaceuticals ALNY:US USD 1.07B 497.67M
Amgen AMGN:US USD 9.5B 4.3B
Arrowhead Research ARWR:US USD 139.44M 53.03M
AstraZeneca AZN:LN USD 4.46B 359M
Biogen BIIB:US USD 3.68B 1.03B
Bristol Myers Squibb BMY:US USD 7.73B 3.02B
Cytokinetics CYTK:US USD 106.24M 12.61M
GlaxoSmithKline GSK:LN GBP 3.61B 2.86B
Karyopharm Therapeutics KPTI:US USD 71.35M 10.9M
Macrogenics MGNX:US USD 83.99M 62.52M
Novartis NOVN:VX USD 8.73B 5.1B
Regeneron Pharmaceuticals REGN:US USD 3.49B 96.2M
Seattle Genetics SGEN:US USD 362.6M 2.27M
Xencor XNCR:US USD 52.65M 3.24M